A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.
Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome …
Real-time market intelligence across asset classes
Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.
| Insider | Role | Date | Type | Value |
|---|---|---|---|---|
| Weingarten Tomer | President, CEO | Jun 15 '26 | Sale | 881306.0 |
| Tomer Weingarten | Officer | Jun 15 '26 | Proposed Sale | 880124.0 |
| Weingarten Tomer | President, CEO | Jun 11 '26 | Sale | 836275.0 |
| Tomer Weingarten | Officer | Jun 11 '26 | Proposed Sale | 845689.0 |
| Weingarten Tomer | President, CEO | Jun 08 '26 | Sale | 615158.0 |
| TOMASELLO ROBIN | Chief Accounting … | Jun 08 '26 | Sale | 186914.0 |
| Conder Keenan Michael | Chief Legal … | Jun 08 '26 | Sale | 131927.0 |
| Weingarten Tomer | President, CEO | May 06 '26 | Sale | 343608.0 |
| TOMASELLO ROBIN | Chief Accounting … | May 06 '26 | Sale | 38477.0 |
| Conder Keenan Michael | Chief Legal … | May 06 '26 | Sale | 71194.0 |
Source: FinViz — Data may be delayed
AI-curated news influencing S price, sentiment, and trend
Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome …
Adjusting sales quotas early in the fiscal year is not surprising, says one analyst who sees weakness in the stock …
Marvell clearly has visibility into big financial opportunities, but analysts wonder about its competitive positioning and the impact of a …
That first losing month may cause some fear, but its a chance to get into the market
The third quarter earnings season has been mostly positive, with most of the reports in the rearview mirror.
The maker of customer relationship management software reports earnings after the bell, and has recently pointed to better times ahead, …
Multi-Provider AI Analysis